Rock Springs Capital Management’s Jasper Therapeutics JSPR Stock Holding History

Rock Springs Capital Management’s Portfolio JSPR Stock Details JSPR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$463K	Hold	1,100,726	–	–	0.02%	102
2026 Q1	$964K	Hold	1,100,726	–	–	0.06%	95
2025 Q4	$2.01M	Hold	1,100,726	–	–	0.1%	90
2025 Q3	$2.62M	Buy	1,100,726 +555,555	+102%	+$1.68M	0.15%	75
2025 Q2	$3.03M	Hold	545,171	–	–	0.19%	72
2025 Q1	$2.34M	Buy	545,171 +82,083	+18%	+$546K	0.13%	77
2024 Q4	$9.9M	Buy	463,088 +4,000	+0.9%	+$83.3K	0.38%	62
2024 Q3	$8.64M	Buy	459,088 +54,753	+14%	+$1.09M	0.28%	71
2024 Q2	$9.18M	Hold	404,335	–	–	0.28%	70
2024 Q1	$11.9M	Buy	+404,335	New	+$7.18M	0.3%	74

Other funds holding JSPR

VCIM

Velan Capital Investment Management Alpharetta, Georgia $164M AUM 542.31% 1-Year Est. Return

ACA

Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return

KCM

Kingdon Capital Management New York $976M AUM 66.76% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Carlyle Group Washington, District of Columbia $10B AUM 10.61% 1-Year Est. Return

GCP

GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

LPC

Lion Point Capital New York $20.9M AUM 195.52% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Rock Springs Capital Management's JSPR Position: Q2 2026 in Review

Rock Springs Capital Management held its Jasper Therapeutics (JSPR) position steady in Q2 2026 at 1,100,726 shares worth $463K. The position accounts for 0.02% of the portfolio, ranked #102.

Rock Springs Capital Management first reported a position in JSPR in Q1 2024 and has held it in 10 quarters since. The position peaked at $11.9M in Q1 2024. 45 funds tracked by Wall St. Rank hold JSPR as of Q2 2026.

Rock Springs Capital Management held 1,100,726 shares of Jasper Therapeutics worth $463K as of Q2 2026.
Rock Springs Capital Management left its Jasper Therapeutics share count unchanged in Q2 2026.
Jasper Therapeutics made up 0.02% of Rock Springs Capital Management's portfolio in Q2 2026, its #102 holding.
Rock Springs Capital Management first reported a position in Jasper Therapeutics in Q1 2024 and has held it in 10 quarters since.
Rock Springs Capital Management's Jasper Therapeutics position peaked at $11.9M in Q1 2024.
45 funds tracked by Wall St. Rank held Jasper Therapeutics as of Q2 2026.

Based on Rock Springs Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.